Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“During the last 14 days, I attended four oncology meetings – one in Luxor and three international webinars, including the Staging and Prognostic Factors Group of the International Association for the Study of Lung Cancer
Across all discussions – lung cancer, mesothelioma, thymoma – one clear direction emerged:
Identify oncogene-driven disease as early as possible.
The focus is shifting from organ-based treatment to molecular subtype–driven strategy.
The question is no longer “Is there a target?” but “How early can we define the biology and act?”
Precision oncology is no longer a concept.
It is becoming a clinical standard.
The future It is about recognizing biological destiny earlier and designing intervention accordingly.”
Other articles featuring Rasha Aboelhassan on OncoDaily.
